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Abstract
Background: The EB peptide is a 20-mer that was previously shown to have broad spectrum in vitro activity
against several unrelated viruses, including highly pathogenic avian influenza, herpes simplex virus type I, and
vaccinia, the prototypic orthopoxvirus. To expand on this work, we evaluated EB for in vitro activity against the
zoonotic orthopoxviruses cowpox and monkeypox and for in vivo activity in mice against vaccinia and cowpox.
Findings: In yield reduction assays, EB had an EC50 of 26.7 μM against cowpox and 4.4 μM against monkeypox.
The EC50 for plaque reduction was 26.3 μM against cowpox and 48.6 μM against monkeypox. A scrambled peptide
had no inhibitory activity against either virus. EB inhibited cowpox in vitro by disrupting virus entry, as evidenced
by a reduction of the release of virus cores into the cytoplasm. Monkeypox was also inhibited in vitro by EB, but at
the attachment stage of infection. EB showed protective activity in mice infected intranasally with vaccinia when
co-administered with the virus, but had no effect when administered prophylactically one day prior to infection or
therapeutically one day post-infection. EB had no in vivo activity against cowpox in mice.
Conclusions: While EB did demonstrate some in vivo efficacy against vaccinia in mice, the limited conditions
under which it was effective against vaccinia and lack of activity against cowpox suggest EB may be more useful
for studying orthopoxvirus entry and attachment in vitro than as a therapeutic against orthopoxviruses in vivo.
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Findings
The EB peptide (NH2- RRKKAAVALLPAVLLALLAP-
COOH) is a 20-mer derived from the signal peptide of the
human FGF4 protein [1] and was originally identified as
an inhibitor of herpes simplex virus entry [2]. Subsequent
work demonstrated that EB was active against several
strains of influenza virus both in vitro and in vivo [3], with
a minimum of 13 core amino acids being identified as
necessary to block influenza attachment to host cells [4].
EB was also identified as an inhibitor of Vaccinia virus
entry into host cells in vitro [5]. This broad range of anti-
viral activity against a number of unrelated viruses, in
combination with low in vivo toxicity [6], makes EB an
attractive candidate for a broad-spectrum antiviral therapy.
Vaccinia virus (VACV) is the most-studied member of
the orthopoxviruses, a genus of large, double-stranded
DNA virus whose most notorious member, Variola virus,
the etiologic agent of smallpox, was declared eradicated in
1980 [7]. Vaccinia virus infection typically results in a self-
limiting infection in immunocompetent individuals; the
closely-related cowpox (CPXV) and monkeypox (MPXV)
viruses, however, are both considered to be emerging zoo-
notic agents [8,9] with the potential to cause serious mor-
bidity and, in the case of MPXV, mortality in infected
hosts [10]. There are currently no FDA-approved thera-
peutics for treating orthopoxvirus infections, and vaccina-
tion is counter-indicated for an increasingly large
percentage of the global population, highlighting the need
for novel therapeutic options. The relatively low global
incidence of severe orthopoxvirus disease, however, makes
identifying broad spectrum drugs with activity against a
number of unrelated viruses, including the orthopox-
viruses, economically advantageous. To expand upon the
initial characterization of EB peptide anti-orthopoxvirus
activity, the goals of this work were to test EB for efficacy
against CPXV and MPXV in vitro,t ob e g i nt od e t e r m i n e
the mechanism for any inhibition observed, and to test EB
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of orthopoxvirus disease, VACV and CPXV.
To determine whether EB had antiviral activity against
CPXV (Brighton strain) and MPXV (Zaire 76 strain), the
effect of increasing concentrations of the peptide (Ameri-
can Peptide Company, Inc., Vista, CA) on virus yield was
determined (Figure 1A). All peptides used were
synthesized with all dextral amino acids to reduce proteo-
lysis. The 50% effective concentration (EC50) of EB against
CPXV was 26.7 μM, while MPXV was more sensitive to
EB with an EC50 of 4.4 μM .T h eE B Xp e p t i d e( N H 2-
RRKLLAALPLVLAAPLAVLA-COOH), a derivative of EB
with a scrambled signal sequence failed to significantly
reduce CPXV or MPXV yield, indicating that the
A Yield Reduction                      B   Plaque Reduction  
Figure 1 EB inhibits CPXV and MPXV in vitro. A) Yield reduction assay. BSC-1 cells in 24-well plates were infected at a m.o.i. of 0.01 with the
indicated virus or with virus pre-treated for one hour with EB. Three days post-infection, cells were harvested by scraping, lysed by repeated
cycles of freezing and thawing, and titered on BSC-1 cells. Data represent the average of three independent assays. B) Plaque reduction assay.
BSC-1 cells in 6-well plates were infected with approximately 100 pfu virus/well with or without peptide. One hr post-infection, the wells were
overlaid with 2% agarose. Plates were fixed 3 days post-infection and plaques were enumerated. Data represent the average of four
independent assays. Circles, CPXV; triangles, MPXV. Closed symbols, EB; opens symbols, EBX.
A CPXV             B   MPXV
  
Figure 2 EB reduces gene expression in CPXV and MPXV. Triplicate wells of BSC-1 cells were infected with recombinant CPXV (A) or
recombinant MPXV (B) expressing GFP under the control of an artificial early/late promoter at a m.o.i. of 1 in the presence of EB for 1 hr at 4°C,
rinsed 3 times, and treated with peptide-containing media. Twenty-four hours post-infection, GFP intensity was measured at 520 nm. Data are
representative of three independent assays.
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Figure 3 Effect of EB on CPXV and MPXV attachment and entry. CPXV (A, B, C, D) or MPXV (E, F) in the presence (B, D, F) or absence (A, C,
E) of 100 μM EB was allowed to attach to BSC-1 cells for 1 hr at room temperature. Samples for attachment staining (A, B, E, F) were fixed with
4% paraformaldehyde, quenched for 5 minutes with 100 mM glycine, blocked with 10% FBS in PBS, and stained with 1:200 anti-VACV antibody
(V0500-11D, US Biologial). Samples for entry staining (C, D) were incubated 1 hr at 37°C prior to PFA fixation, glycine quenching, permeabilization
with 0.1% saponin, and staining with anti-core antibody (R236). Nuclei were counterstained with DAPI (blue). Arrows indicate selected virions
(green) or virus cores (red).
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cific. EB was also active against CPXV and MPXV in pla-
que reduction assays, with EC50 values of 26.3 and 48.6
μM, respectively, whereas EBX had no effect on either
virus (Figure 1B). The different susceptibilities of CPXV
and MPXV to EB in these two assays suggested that EB
was acting differently on the two viruses. As EBX showed
no activity against either virus, it was not included in
further assays.
EB was next tested for its ability to reduce gene expres-
sion during CPXV and MPXV infections (Figure 2). BSC-
1 cells were infected with recombinant CPXV or MPXV
expressing GFP under the control of a synthetic early/
late promoter in the presence of increasing concentra-
tions of EB. The EB peptide reduced GFP expression by
both viruses, with an EC50 of 26.7 μM against CPXV and
27.6 μM against MPXV, indicating that EB acted
upstream of gene expression to inhibit both viruses.
Orthopoxvirus cores are only accessible to antibodies
after being released into the cytoplasm, allowing for the
differentiation between attached and entered virus using
virion-specific or core-specific antibodies, respectively
[11]. To examine whether EB was disrupting virus attach-
ment or entry into the cells, immunofluorescent
microscopy was used to quantify the number of attached
and entered viruses per cell for 100 cells in the absence or
presence of 100 μM EB. The presence of EB had no signif-
icant effect on the number of CPXV virions attached to
cells (5.4 virions/cell, untreated vs.4.7 virions/cell, treated,
p >0 . 0 1 ;F i g u r e3 A vs. 3B) but significantly reduced virus
entry (1.3 cores/cell, untreated vs. 0.3 cores/cell, treated, p
< 0.0001; Figure 3Cvs. 3D). These data are similar to what
has been reported with VACV, where virus attachment
was unaffected by peptide treatment but core release was
significantly reduced [5]. In contrast, MXPV attachment
was significantly inhibited by EB (3.2 virions/cell,
untreated vs. 0.9 virions/cell, treated, p <0 . 0 0 1 ;F i g u r e
3Evs. 3F). Based on the observed disruption of virus
attachment, MPXV entry was not examined. This different
target of inhibition is consistent with the different pattern
of EB susceptibility displayed by MPXV in the yield reduc-
tion assay compared to that demonstrated by CPXV and
VACV. As inhibition of both CPXV and MPXV by EB
occurs extracellularly, it is unlikely that the peptide’s pre-
viously-described ability to inhibit NF-B signaling [1] is
involved in its anti-orthopoxvirus activity.
EB has shown efficacy in an in vivo model of lethal
influenza infection when added at the time of infection
Figure 4 In vivo activity of EB. Ten female BALB/c mice were inoculated intranasally with 20 μL containing 10
5 PFU VACV (Control) or 10
5 PFU
VACV mixed with10 mg/kg EB (Single dose) in PBS on day 0. One additional group of animals received a second dose of EB intranasally on day
3 (Two doses). Animal survival was monitored for 21 days, and mice were euthanized when they met established endpoint criteria.
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been tested against any orthopoxviruses. As there is cur-
rently no well-characterized mouse model for MPXV
infection available, EB was only tested against VACV
(strain WR) and CPXV (strain Brighton) in vivo. To test
EB for in vivo efficacy against VACV, EB (10 mg/kg)
was administered intranasally concurrently with 10
5
PFU of VACV (strain WR). Seventy percent of infected
animals treated with a single dose of EB at the time of
infection survived to study end, compared to no survi-
vors in untreated animals (Figure 4). Two doses of EB
(day 0, day 3) were less effective than a single dose, with
only 20% of animals surviving. Animals receiving 2
doses met clinical endpoint criteria slightly earlier than
control animals, which may suggest that further intrana-
sal treatment exacerbated disease. EB showed no efficacy
when administered prophylactically (1 day pre-infection)
or therapeutically (1 day post-infection) to VACV-
infected mice (data not shown). EB also demonstrated
no efficacy when administered prophylactically, at the
time of infection, or therapeutically to mice infected
intranasally with CPXV (data not shown).
In summary, we were able to demonstrate in vivo effi-
cacy of EB against VACV but not CPXV, despite both
viruses having similar sensitivities to the peptide in
vitro. The reasons for this difference are as yet unclear.
EB was only effective against VACV when co-adminis-
tered with the virus, suggesting that the peptide needed
direct interaction with the virus to be effective. EB self-
associates in micelle-like structures at high concentra-
tions and in high ionic buffers [12], a property which
could influence bioavailability. It is possible that the in
vivo anti-orthopoxvirus activity could therefore be
improved by changing the vehicle used for delivery.
Most intriguing is the observation that EB inhibited
attachment by MPXV but blocked entry by CPXV, as
t h e s ep r o c e s s e sa r eg e n e r a l l yb e l i e v e dt ob eh i g h l yc o n -
served between the orthopoxviruses. While EB has now
been shown to have activity in vivo against VACV and
influenza viruses [3], its greatest potential with ortho-
poxviruses may be as a novel in vitro tool to study the
poorly-characterized early steps in infection. To date,
over a dozen viral proteins are believed to be involved
in orthopoxvirus attachment and entry [13-25]. The pre-
cise mechanisms of attachment and entry, however, have
yet to be elucidated. Identification of the precise targets
of the interaction between EB and VACV, CPXV, and
MPXV could help identify key amino acids or structural
features necessary for these processes and identify tar-
gets for novel inhibitors of infection.
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